With Gilead’s Lock In Hepatitis C, What’s Next For The Field?
Executive Summary
The competition in HCV is virtually concluded, as Gilead exited the AASLD conference holding a best-in-class advantage in terms of efficacy and convenience. Its hold on the market may prove impregnable for other comers, but as Yogi Berra said, “It ain’t over till it’s over.”
You may also be interested in...
Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV
With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.